Ehlers-Danlos Syndrome Clinical Trials and Treatments

Ehlers-Danlos syndrome (EDS) encompasses a group of genetic connective tissue disorders, most caused by mutations affecting collagen synthesis, structure, or processing. Hypermobile EDS, the most common type, has no known gene and is diagnosed on clinical criteria. At least 13 subtypes are recognized, each with distinct genetic basis and clinical features.

The most common symptoms of Ehlers-Danlos Syndrome include Overly flexible joints (hypermobility) with dislocations, Hyperextensible, velvety skin with poor wound healing, Easy bruising and fragile tissues, Aortic and arterial aneurysms in vascular EDS, Gastrointestinal complications including perforations in vascular EDS, among others. At least 1 in 5,000 people overall (varies by subtype; the vascular form affects at least 1 in 150,000, per GeneReviews). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Ehlers-Danlos Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research into EDS is moving beyond symptom management toward therapies designed for specific types. Researchers are working on pain management, ways to improve wound healing and reduce skin fragility, and treatments aimed at the genetic cause of a particular type.

As of October 21, 2026, no current FDA drug label names Ehlers-Danlos Syndrome as a condition the drug treats.

Ehlers-Danlos Syndrome is caused by variants in any of many genes, most often COL5A1, COL5A2, COL3A1, COL1A1, COL1A2 and TNXB. At least 20 genes are known across the subtypes, but hypermobile EDS, the most common type, has no identified gene and remains a clinical diagnosis.

It follows autosomal dominant or recessive depending on type inheritance. At least 1 in 5,000 people overall (varies by subtype; the vascular form affects at least 1 in 150,000, per GeneReviews). A multigene panel identifies the cause in most families.

Yes. Ehlers-Danlos Syndrome can be caused by variants in many different genes (COL5A1, COL5A2, COL3A1, COL1A1, COL1A2 and TNXB are among the most common), so testing is usually a multigene panel or exome sequencing rather than one gene at a time. At least 20 genes are known across the subtypes, but hypermobile EDS, the most common type, has no identified gene and remains a clinical diagnosis.

It follows autosomal dominant or recessive depending on type inheritance.

Knowing the exact gene matters: it decides which trials a patient qualifies for and which relatives should be tested. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Ehlers-Danlos Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Ehlers-Danlos Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.